Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan/HCTZ as first-line treatment for moderate hypertension
NCT00095550Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) comparing Irbesartan/HCTZ with Irbesartan (2 arms). Primary endpoint: Change from baseline in Sitting Systolic Blood Pressure at 8 weeks. Started Oct 2004; status: completed.
02
Drugs
irbesartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00095550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095550.